Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

Authors :: Renaud Sabatier
Frédérique Rousseau
Florence Joly
Claire Cropet
Coline Montégut
Johanna Frindte
Saverio Cinieri
Eva M. Guerra Alía
Stephan Polterauer
Hiroyuki Yoshida
Ignace Vergote
Nicoletta Colombo
Sakari Hietanen
Rémi Largillier
Ulrich Canzler
Alain Gratet
Frederik Marmé
Laure Favier
Eric Pujade-Lauraine
Isabelle Ray-Coquard
Sabatier, R
Rousseau, F
Joly, F
Cropet, C
Montegut, C
Frindte, J
Cinieri, S
Guerra Alia, E
Polterauer, S
Yoshida, H
Vergote, I
Colombo, N
Hietanen, S
Largillier, R
Canzler, U
Gratet, A
Marme, F
Favier, L
Pujade-Lauraine, E
Ray-Coquard, I
Source :: European Journal of Cancer. 181:42-52
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.
Abstract: BACKGROUND: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. METHODS: Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (

Subjects :: Cancer Research
Elderly
Olaparib
Survival
Oncology
Ovarian cancer
Safety

Full Text Access

Tools